HighTide Therapeutics, Inc. (02511)

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

HighTide Therapeutics, Inc. (02511)

HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of therapies for the treatment of metabolic and digestive diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis; in phase III clinical trial to treat type 2 diabetes mellitus; is in phase

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907) holding Type 1 Licence for Dealing in Securities, Type 4 Licence for Advising on Securities, Type 6 Licence for Advising on Corporate Finance, and Type 9 Licence for Asset Management.

Market News

HighTide Therapeutics, Inc. (02511)

Services

About Us

Agreement Statement